ABSTRACT
I. INTRODUCTION A. Objectives of the Chapter This chapter gives a brief account of how selectively acting ,8-adrenoceptor agonists and glucocorticoid steroids were developed in Glaxo-Allenburys Laboratories for use by inhalation in asthma and of their therapeutic use. It is written in tribute to the colleagues and clinical investigators whose efforts have transformed the treatment of asthma during the past 30 years and in the hope that it may lead to better understanding and use of these drugs. The views expressed are, however, personal and may not accord with those of former colleagues or with current medical opinion.
